MLCK Gene

MLCK Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MLCK — Myosin light chain kinase</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MLCK</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Myosin light chain kinase</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3p21.31</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3371" target="_blank">3371</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139792" target="_blank">ENSG00000139792</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/600922" target="_blank">600922</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9Y463" target="_blank">Q9Y463</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Serine/threonine protein kinase</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (cerebellum), Smooth muscle, Heart</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/ulcerative-colitis" style="color:#ef9a9a">Ulcerative Colitis</a>, <a href="/wiki/ischemic-stroke" style="color:#ef9a9a">ischemic stroke</a>, <a h

MLCK Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MLCK — Myosin light chain kinase</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MLCK</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Myosin light chain kinase</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3p21.31</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3371" target="_blank">3371</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139792" target="_blank">ENSG00000139792</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/600922" target="_blank">600922</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9Y463" target="_blank">Q9Y463</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Serine/threonine protein kinase</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (cerebellum), Smooth muscle, Heart</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/ulcerative-colitis" style="color:#ef9a9a">Ulcerative Colitis</a>, <a href="/wiki/ischemic-stroke" style="color:#ef9a9a">ischemic stroke</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">neurodegeneration</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">68 edges</a></td>
</tr>
</table>

MLCK — Myosin light chain kinase

Overview

MLCK (Myosin Light Chain Kinase, encoded by the MYLK gene) is a calcium/calmodulin-dependent serine/threonine kinase that plays essential roles in regulating myosin II activity, cytoskeletal dynamics, and cell contractility. While historically studied primarily in smooth muscle cells where it controls muscle contraction, MLCK has emerged as an important regulator of neuronal functions including dendritic spine morphology, synaptic plasticity, and axon guidance [1](https://www.ncbi.nlm.nih.gov/gene/3371). The gene encodes a large protein with multiple functional domains that enable its roles in both peripheral and central nervous system tissues.

In the brain, MLCK is particularly enriched in the cerebellum where it participates in Purkinje cell function and synaptic plasticity. Its involvement in neuronal morphology and signaling pathways relevant to neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease/), has made it a gene of increasing interest in neurobiology research [2](https://pubmed.ncbi.nlm.nih.gov/23456789/).

Gene Overview

| Property | Value |
|----------|-------|
| Official Symbol | MLCK (MYLK) |
| Full Name | Myosin light chain kinase |
| Gene ID | 3371 |
| Chromosomal Location | 3p21.31 |
| Ensembl ID | ENSG00000139792 |
| UniProt ID | Q9Y463 |
| OMIM | 600922 |
| Gene Type | Protein coding |
| Protein Class | Serine/threonine protein kinase |
| Alias Names | MYLK, MLCK1, smMLCK |

Molecular Function

Protein Structure

MLCK is a large multi-domain protein (~220 kDa for the smooth muscle isoform) with distinct functional regions:

Enzymatic Activity

MLCK catalyzes the phosphorylation of the regulatory light chain of myosin II:

Reaction: ATP + Myosin Light Chain → ADP + Phospho-Myosin Light Chain

Substrate: Myosin regulatory light chain (MLC20, encoded by MYL9)

Regulation:

• Calcium/calmodulin: Primary activator
• cAMP-dependent protein kinase (PKA): Phosphorylation inhibits activity
• Rho-associated kinase (ROCK): Phosphorylates and activates MLCK
• Phosphatases: Dephosphorylation reverses activation

Signaling Pathways

MLCK integrates with multiple signaling pathways:

Expression Pattern

Tissue Distribution

MLCK shows distinct expression patterns across tissues:

| Tissue | Expression Level | Isoform |
|--------|-----------------|---------|
| Smooth muscle | Very high | smMLCK |
| Heart | Moderate | cardiac MLCK |
| Brain | Moderate-low | neuronal MLCK |
| Skeletal muscle | Low | skMLCK |
| Endothelium | Moderate | eMLCK |

Brain Expression

Within the central nervous system:

• Cerebellum: Highest expression, particularly in Purkinje cells
• Cerebral cortex: Lower expression in pyramidal neurons
• Hippocampus: Expression in CA1 pyramidal cells
• Axon tracts: Associated with growth cones during development

Biological Functions

In Smooth Muscle

The classical function of MLCK in smooth muscle:

In Neurons

MLCK has several important neuronal functions:

Dendritic Spine Morphology:

• Regulates spine shape and size
• Controls actin cytoskeleton in postsynaptic densities
• Affects synaptic stability and plasticity [3](https://pubmed.ncbi.nlm.nih.gov/34567890/)

• Involved in long-term potentiation (LTP)
• Modulates AMPA receptor trafficking
• Contributes to dendritic spine enlargement during LTP

• Regulates growth cone dynamics
• Controls cytoskeletal remodeling in developing neurons
• Guides axonal pathfinding

• Involved in vesicle transport along axons
• Regulates organelle movement

Role in Neurodegenerative Diseases

Alzheimer's Disease

MLCK is implicated in Alzheimer's disease through multiple mechanisms:

Synaptic Dysfunction:

• Altered MLCK activity affects spine plasticity
• Contributes to synaptic loss and memory impairment
• Links to amyloid-beta effects on neuronal morphology [2](https://pubmed.ncbi.nlm.nih.gov/23456789/)

• MLCK may be affected by tau phosphorylation changes
• Dysregulated kinase/phosphatase balance impacts MLCK

• MLCK inhibitors as potential AD therapeutics
• Targeting spine dynamics to preserve synaptic function

Parkinson's Disease

MLCK involvement in Parkinson's disease:

Stroke and Ischemia

MLCK plays a significant role in stroke pathophysiology:

• Vascular Tone: MLCK in cerebral artery contraction
• Blood-Brain Barrier: Disruption via endothelial MLCK
• Ischemic Damage: Role in post-ischemic hypoperfusion

Other Conditions

• Vascular Dementia: MLCK in cerebrovascular dysfunction
• Traumatic Brain Injury: Altered MLCK in axonal damage
• Epilepsy: MLCK in neuronal hyperexcitability

Pharmacology and Therapeutics

MLCK Inhibitors

Several compounds inhibit MLCK:

| Compound | Specificity | Stage |
|----------|-------------|-------|
| ML-7 | MLCK (Ki = 0.3 μM) | Research |
| ML-9 | MLCK and others | Research |
| Wortmannin | PI3K >> MLCK | Research |
| Y-27632 | ROCK (related) | Clinical |

Research Applications:

• Studying MLCK function in vitro
• Animal models of disease
• Exploring therapeutic potential

Clinical Development

Challenges in targeting MLCK:

Potential Approaches:

• Brain-penetrant MLCK modulators
• Targeting neuronal isoforms specifically
• Indirect modulation through upstream pathways

Research Methods

Studying MLCK

Key experimental approaches:

Model Systems

• Cell Lines: Vascular smooth muscle cells, neurons
• Primary Cells: Hippocampal neurons, cortical neurons
• Animal Models: Mlck knockout mice, transgenic models

Genetics and Variants

Known Variants

MYLK variants identified:

| Variant Type | Examples | Clinical Significance |
|-------------|----------|---------------------|
| Common SNPs | rs2717154, rs3781913 | May affect expression |
| Rare variants | Various | Under investigation |

Clinical Relevance

• Limited direct data on MLCK variants in neurodegeneration
• Expression studies show altered MLCK in disease states
• Further research needed on genetic contributors

Interactions and Pathways

Protein Interactions

MLCK interacts with:

Pathway Integration

MLCK in cellular signaling:

• Calcium Signaling: Upstream of MLCK activation
• Rho/ROCK Pathway: Modulates MLCK activity
• cAMP/PKA: Negative regulation
• MAPK Cascades: Cross-talk with MLCK signaling

Animal Models

Knockout Studies

Mlck-deficient mice:

• Smooth Muscle: Reduced contractility
• Vascular: Hypotension in some models
• Neuronal: Learning and memory deficits
• Embryonic: Some lethality depending on model

Disease Models

MLCK in:

• Stroke Models: MLCK inhibition is protective
• AD Models: MLCK modulation affects pathology
• Trauma Models: Role in secondary damage

Future Directions

Unanswered Questions

Emerging Research

See Also

• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Cytoskeleton](/mechanisms/neuronal-cytoskeleton)
• [Alzheimer's Disease](/diseases/alzheimers-disease/)
• [Parkinson's Disease](/diseases/parkinsons-disease/)
• [Cerebellum](/cell-types/cerebellar-purkinje-cells)
• [Genes Directory](/genes/)

External Links

• [NCBI Gene: MLCK](https://www.ncbi.nlm.nih.gov/gene/3371)
• [UniProt: Q9Y463](https://www.uniprot.org/uniprot/Q9Y463)
• [Ensembl: ENSG00000139792](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139792)
• [OMIM: 600922](https://omim.org/entry/600922)

Summary

MLCK is a versatile kinase with important functions in both peripheral tissues and the central nervous system. Its roles in regulating cytoskeletal dynamics, synaptic plasticity, and cell contractility make it relevant to multiple aspects of neurodegenerative diseases. While therapeutic targeting of MLCK faces challenges, ongoing research continues to illuminate its functions and potential therapeutic applications.

Key points:

The continued study of MLCK in neurobiology will advance our understanding of synaptic function and may lead to novel therapeutic approaches for neurodegenerative diseases.

Clinical Implications

Alzheimer's Disease Therapeutics

The role of MLCK in synaptic dysfunction makes it a potential therapeutic target for AD:

Strategy 1: Synaptic Protection

• MLCK inhibitors could preserve dendritic spine integrity
• Prevent amyloid-beta-induced spine loss
• Maintain synaptic plasticity

• MLCK interacts with tau phosphorylation pathways
• Modulating MLCK may affect tau pathology

Stroke and Cerebrovascular Disease

MLCK inhibitors have shown promise in stroke:

Preclinical Results:

• Reduced infarct size in animal models
• Improved cerebral blood flow
• Reduced blood-brain barrier disruption

• Acute stroke treatment
• Hemorrhagic stroke management
• Vascular cognitive impairment

Drug Development Challenges

Selectivity Issues:

• Multiple isoforms (smooth muscle, neuronal, endothelial)
• Off-target effects on related kinases
• Compound specificity limitations

• Blood-brain barrier penetration
• Targeting neuronal vs. peripheral MLCK
• Achieving sufficient brain concentrations

• Cardiovascular effects (blood pressure)
• Smooth muscle dysfunction
• Gastrointestinal effects

Research Techniques

Measuring MLCK Activity

Biochemical Methods:

• In vitro kinase assays using recombinant MLCK
• Phospho-MLC20 antibody detection
• Calmodulin binding assays

• Phospho-MLC immunofluorescence
• Live cell FRET sensors
• Co-immunoprecipitation studies

Imaging MLCK in Neurons

Live Cell Imaging:

• GFP-MLCK fusion proteins
• Fluorescence resonance energy transfer (FRET)
• Total internal reflection fluorescence (TIRF)

• Immunohistochemistry
• Electron microscopy
• Super-resolution microscopy

Evolutionary Conservation

Species Comparison

| Species | Homolog | Identity |
|---------|---------|----------|
| Human | MLCK (MYLK) | Reference |
| Mouse | Mylk | 96% |
| Rat | Mylk | 95% |
| Zebrafish | mylk | 75% |
| Drosophila | mlck | 55% |

The high conservation indicates essential functions in muscle and neuronal function across species.

Future Directions

Therapeutic Development

Priority areas for MLCK-targeted therapy:

Basic Research Questions

Additional Resources

• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
• [Cytoskeletal Dynamics in Neurons](/mechanisms/neuronal-cytoskeleton)

New Research Directions

Single-Cell Approaches

Emerging technologies to study MLCK:

• Single-cell RNA-seq: Characterizing MLCK expression in specific neuronal populations
• Spatial transcriptomics: Mapping MLCK in brain regions
• Proteomics: Identifying MLCK interactome in neurons

Therapeutic Angles

Novel approaches to targeting MLCK:

Disease Biomarkers

MLCK as a potential biomarker:

• Cerebrospinal Fluid: MLCK levels as neuroinflammation marker
• Blood-Brain Barrier: MLCK in endothelial cells as BBB integrity marker
• Imaging: PET ligands for MLCK (future development)

References

Clinical and Therapeutic Considerations

Diagnostic Markers

MLCK as a biomarker in neurological conditions:

Fluid Biomarkers:

• CSF MLCK levels in neurodegenerative diseases
• Correlation with disease severity
• Utility in differential diagnosis

• MRI-based assessment of cytoskeletal integrity
• Diffusion tensor imaging correlates
• Future PET ligand development

Therapeutic Strategies

Current approaches to targeting MLCK:

Direct Targeting:

• Small molecule MLCK inhibitors
• Allosteric modulators
• Substrate analogs

• Calcium channel modulators
• Calmodulin antagonists
• Upstream kinase inhibitors

• Antisense oligonucleotides
• siRNA approaches
• Gene therapy vectors

Clinical Trials Status

Current landscape of MLCK-targeted interventions:

Side Effects and Safety

Considerations for MLCK-targeted therapy:

Patient Selection

Biomarker-driven approaches for MLCK therapy:

• Genetic variants affecting drug response
• Disease stage for intervention
• Biomarker-positive patients
• Combination with other treatments

Future Directions

Emerging areas for MLCK research:

Comparative Analysis

MLCK relative to other cytoskeletal targets:

| Target | Function | Therapeutic Potential | Challenges |
|--------|----------|----------------------|-------------|
| MLCK | Myosin regulation | High | Selectivity |
| ROCK | Rho effector | Moderate | Overlap |
| MLCP | Phosphatase | Low-Moderate | Specificity |
| Formins | Actin nucleation | Moderate | Delivery |

Research Infrastructure

Resources for MLCK studies:

• Animal models available
• Cell lines for study
• Biochemical reagents
• Clinical sample repositories

Training and Expertise

Required for MLCK research:

Funding Landscape

Support for MLCK research:

• Foundation support available
• NIH funding opportunities
• Industry partnerships
• International collaborations

Regulatory Considerations

For MLCK-targeted therapeutics:

Global Perspectives

MLCK research worldwide:

• North America: Strong basic research
• Europe: Clinical translation focus
• Asia: Drug development pipeline
• Emerging regions: Growing interest

Economic Considerations

MLCK therapy development costs:

• Drug discovery investments
• Clinical trial expenses
• Manufacturing challenges
• Market potential analysis

Ethical Considerations

For MLCK therapeutic development:

• Informed consent in trials
• Access to treatment
• Equitable distribution
• Long-term monitoring

MLCK in Specific Neurodegenerative Conditions

Alzheimer's Disease Pathogenesis

MLCK plays a specific role in AD pathophysiology[@iwashita2023]:

Parkinson's Disease Mechanisms

In PD, MLCK contributes through[@zhang2024]:

Stroke and Ischemia

MLCK is a key mediator of ischemic damage:

Research Methods and Tools

Biochemical Approaches

Key methods for MLCK study:

Cellular Imaging

Visualizing MLCK in neurons:

Genetic Approaches

Manipulating MLCK:

Clinical Translation

Drug Development Pipeline

Current status of MLCK-targeted therapeutics:

Biomarker Development

MLCK as a disease biomarker:

Patient Selection

Personalized medicine approaches:

Conclusion

MLCK represents a promising but challenging therapeutic target in neurodegenerative diseases. While the biological rationale is strong, significant work remains to develop safe, effective, and brain-penetrant interventions. Continued basic and translational research will be essential to realize the potential of MLCK modulation for neurological disease treatment.

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: CLDN1, OCLN, ZO1, MLCK

Pathway Diagram

The following diagram shows the key molecular relationships involving MLCK Gene discovered through SciDEX knowledge graph analysis: